NCT01273389View on ClinicalTrials.gov

An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Lupus Nephritis
Interventions
DRUG

CNTO 136

Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous. CNTO 136 is administered once every 4 weeks from Week 0 to Week 24.

DRUG

Placebo

Form=solution for injection, route=intravenous. Placebo is administered once every 4 weeks from Week 0 to Week 24.

Trial Locations (21)

Unknown

Birmingham

Los Angeles

Chicago

Lake Success

Columbus

Duncansville

Chattanooga

Carrollton

Brussels

Leuven

Roeselare

Guadalajara

Guadalajara, Jalisco

México

Querétaro

Rotterdam

Gdansk

Warsaw

Wroclaw

Bangkok

Chiang Mai

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01273389 - An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis | Biotech Hunter | Biotech Hunter